Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide first-line treatment in treatment-naive adults with HIV-1 infection and severe immunosuppression
2017-004137-91Phase 4Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Virologic success at week 48. Started Dec 2017; status: active.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-004137-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004137-91.